Accelerating Entry into Central and South American Markets: Hanmi Pharmaceutical Signs Diabetes Drug Supply Agreement with Mexico

Partner Company "Silanes" Continues to Expand Collaborative Product Portfolio

Hanmi Pharmaceutical announced on September 15 that it has signed a license and supply agreement for a diabetes combination drug with Mexican pharmaceutical company Silanes.

Under this agreement, Hanmi Pharmaceutical will supply the product, while Silanes will be responsible for obtaining approval, distribution, and sales within Mexico. The two companies have maintained a strategic partnership since 2019 and have continued to strengthen their collaborative relationship.

Founded in 1943, Silanes is a leading pharmaceutical company in Mexico. Leveraging its robust distribution network and global collaboration channels, it has established itself as a major pharmaceutical player in Central and South America. In particular, Silanes holds the top market share among local companies in the field of diabetes treatments, securing a dominant position in the market.

Silanes has shown significant interest in Hanmi Pharmaceutical's combination drug technology, which enhances patient compliance and convenience. Since 2023, the two companies have continued to expand their collaborative product portfolio by sequentially launching Amosartan Q (a combination drug for hypertension and hyperlipidemia), Amosartan Plus (a treatment for hypertension), and Gugutams (a combination drug for benign prostatic hyperplasia and erectile dysfunction).

In May, the Silanes business development team visited Hanmi Pharmaceutical's headquarters and the Paltan Smart Plant to inspect advanced manufacturing facilities and quality control systems. Through this visit, Silanes reportedly expressed strong confidence in Hanmi Pharmaceutical's global production capabilities.

Prior to signing this agreement, Park Jaehyun, CEO of Hanmi Pharmaceutical, visited Silanes' headquarters and production facilities to directly review the manufacturing processes and quality control systems, gaining insights into the local market environment. During this meeting, the two companies held in-depth discussions on future marketing strategies and product launch plans.

A representative of Hanmi Pharmaceutical stated, "This agreement is an important achievement that demonstrates the global competitiveness of our combination drug technology," adding, "We will continue to pursue overseas business expansion, using our entry into the Mexican market as a stepping stone."

This content was produced with the assistance of AI translation services.